An update on immune-based alpha-synuclein trials in Parkinson’s disease DOI Creative Commons

Maha Alfaidi,

Roger A. Barker, Wei‐Li Kuan

et al.

Journal of Neurology, Journal Year: 2024, Volume and Issue: 272(1)

Published: Dec. 12, 2024

Abstract Parkinson’s disease (PD) is a prevalent, chronic neurodegenerative disorder characterised by the progressive loss of dopaminergic neurons in substantia nigra and other brain regions. The aggregation alpha-synuclein (α-syn) into Lewy bodies neurites key pathological feature associated with PD its progression. Many therapeutic studies aim to target these aggregated forms α-syn potentially slow down or stop progression PD. This review provides comprehensive analysis recent clinical trials involving vaccines monoclonal antibodies targeting α-syn. Specifically, UB-312, AFFITOPE PD01A, PD03A ACI-7104.056 are designed provoke an immune response against (active immunisation), while Prasinezumab Cinpanemab, MEDI1341 Lu AF82422 focus on directly aggregates (passive immunisation). Despite some promising results, challenges such as variable efficacy trial discontinuations persist. Future research must address advance disease-modifying therapies for around this target.

Language: Английский

Identifying brain degeneration patterns in early-stage Parkinson’s disease: a multimodal MRI study DOI Creative Commons
Zihao Zhu, Jiaqi Wen,

Xiaojie Duanmu

et al.

npj Parkinson s Disease, Journal Year: 2025, Volume and Issue: 11(1)

Published: April 25, 2025

Parkinson's disease (PD) is a highly heterogeneous neurodegenerative disorder. This study aimed to identify different patterns of early brain degeneration in PD patients and investigate their clinical relevance. 179 early-stage 115 healthy controls were included. We assessed cortical morphology, white matter microstructure, subcortical iron metabolism using multimodal magnetic resonance imaging employed clustering techniques subtypes. Two subtypes identified: the early-deterioration subtype, characterized by fronto-temporal atrophy, parietal thickening, widespread reductions fractional anisotropy (FA) values, increased content, which exhibited more severe baseline symptoms trend faster memory decline; early-compensatory rostral middle frontal parietal-occipital FA normal milder initially but experienced progression both motor non-motor symptoms. These discoveries provided new insights into heterogeneity facilitated exploration mechanisms.

Language: Английский

Citations

0
An update on immune-based alpha-synuclein trials in Parkinson’s disease DOI Creative Commons

Maha Alfaidi,

Roger A. Barker, Wei‐Li Kuan

et al.

Journal of Neurology, Journal Year: 2024, Volume and Issue: 272(1)

Published: Dec. 12, 2024

Abstract Parkinson’s disease (PD) is a prevalent, chronic neurodegenerative disorder characterised by the progressive loss of dopaminergic neurons in substantia nigra and other brain regions. The aggregation alpha-synuclein (α-syn) into Lewy bodies neurites key pathological feature associated with PD its progression. Many therapeutic studies aim to target these aggregated forms α-syn potentially slow down or stop progression PD. This review provides comprehensive analysis recent clinical trials involving vaccines monoclonal antibodies targeting α-syn. Specifically, UB-312, AFFITOPE PD01A, PD03A ACI-7104.056 are designed provoke an immune response against (active immunisation), while Prasinezumab Cinpanemab, MEDI1341 Lu AF82422 focus on directly aggregates (passive immunisation). Despite some promising results, challenges such as variable efficacy trial discontinuations persist. Future research must address advance disease-modifying therapies for around this target.

Language: Английский

Citations

0